Table 1.
Sequence analysis results for resistance-associated mutations in the polymerase sequence (P) of samples and their rating as determined by DRI and G2P
| Mutation in P associated with drug resistancea | Interpretationb |
No. of strainsc (%) | |
|---|---|---|---|
| DRI | G2P | ||
| T184S | I, entecavir | I, entecavir | 1 (4.5) |
| M204I | R, lamivudine; R, telbivudine | R, lamivudine; R, telbivudine | 7 (32) |
| N236T | R, adefovir | R, adefovir | 1 (4.5) |
| A181V, N236T | R, adefovir | R, adefovir; I, lamivudine | 1 (4.5) |
| A181T, M204I | R, lamivudine; R, telbivudine | R, lamivudine; R, telbivudine; I, tenofovir | 1 (4.5) |
| L180M, M204I | R, lamivudine; R, telbivudine; I, entecavir | R, lamivudine; R, telbivudine | 1 (4.5) |
| L180M, M204V | R, lamivudine; R, telbivudine; I, entecavir | R, lamivudine; R, telbivudine | 6 (27) |
| L180M, T184A, M204V | R, lamivudine; R, telbivudine; R, entecavir | R, lamivudine; R, entecavir; I, telbivudine | 1 (4.5) |
| L180M, T184S, M204V | R, lamivudine; R, telbivudine; R, entecavir | R, lamivudine; R, entecavir; I, telbivudine | 1 (4.5) |
| V173L, L180M, M204V | R, lamivudine; R, telbivudine; I, entecavir | R, lamivudine; I, telbivudine | 2 (9) |
a
All positions refer to codons in P.
b
I, intermediate (DRI) or possible (G2P) resistance; R, resistance. Discordant interpretations in the algorithms are indicated by gray shading. DRI, HIV-grade HBV drug resistance interpretation; G2P, Geno2pheno[HBV] result.
c
That is, the number of strains with the respective mutation.